Viking Therapeutics Faces Mounting Pressure in Oral Obesity Drug Race

Viking Therapeutics contends with insider selling and strong Phase 2 data from Structure Therapeutics' oral GLP-1 drug, raising the competitive bar in obesity treatment.

The competitive landscape for oral GLP-1 obesity treatments is intensifying. Viking Therapeutics finds itself navigating a dual challenge: compelling new clinical data from a rival and a notable pullback by key institutional shareholders.

Institutional and Insider Selling Activity

Recent regulatory filings reveal a shift in sentiment among major investors. Granahan Investment Management LLC significantly reduced its stake, selling 115,562 shares—a 37.9% decrease in its position. The firm now holds 189,529 shares valued at approximately $4.98 million. Overall institutional ownership currently stands at 76.03%.

This trend extends to the company's leadership. In the last quarter, CEO Brian Lian and CFO Greg Zante sold 233,409 and 57,661 shares, respectively. Combined, insider sales totaled roughly 364,731 shares, with a collective market value of about $12.05 million. The insider ownership percentage has consequently moved to 4.10%.

A Formidable New Competitor Emerges

Adding to the pressure, Structure Therapeutics released impressive Phase 2 results for its oral GLP-1 agonist, Aleniglipron, on March 16. The data showed a placebo-adjusted weight reduction of up to 16.3% over a 44-week period. Perhaps more striking was the low discontinuation rate due to adverse events, which stood at just 3.7%, suggesting the drug candidate is well-tolerated.

The company has outlined an aggressive development timeline, scheduling an End-of-Phase 2 meeting with the FDA for the second quarter of 2026. It aims to initiate a Phase 3 trial before the end of that same year. This accelerated schedule is raising the stakes across the entire oral weight-loss segment.

While a direct head-to-head comparison of data is not yet fully possible, Aleniglipron's strong performance has undoubtedly raised the bar. The coming months will be critical for Viking to demonstrate clear clinical differentiation, especially as its competitor advances into late-stage studies.

Analyst Sentiment Holds Steady Amidst Shifts

Despite the selling activity, the consensus view among market analysts remains largely positive, maintaining a "Moderate Buy" rating. Morgan Stanley has assigned an "Overweight" recommendation with a price target of $99 per share. The consensus price target across covering firms is $87.80. Weiss Research stands as a notable outlier, maintaining a "Sell" rating on the stock.

This prevailing optimism from research analysts presents a contrast to the recent divestments by institutional funds and insiders. The path forward for Viking Therapeutics will hinge on its ability to distinguish its clinical profile from emerging rivals like Structure Therapeutics, particularly as more comparative data becomes available.